Docetaxel for the treatment of hormone-refractory metastatic prostate cancer

Review decision: May 2012 information

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 111 KB)

Prostate cancer (hormone-refractory) - docetaxel: review proposal - March 2012 information

Appendix A: provisional matrix of stakeholders (PDF 56 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 114 KB)

Review decision - August 2009 information

Review decision - August 2009: appendix A - decision paper (PDF 58 KB)

Review proposal - June 2009 information

Provisional matrix of consultees and commentators (PDF 34 KB)

Prostate cancer (hormone-refractory) - docetaxel: Consultee and commentator comments on the ACD 

British Prostate Group (PDF 50 KB)

Department of Health (PDF 13 KB)

Institute of Cancer Research (PDF 80 KB)

NHS Quality Improvement (PDF 27 KB)

Prostate Cancer Charity (PDF 44 KB)

Royal College of Pathologists (PDF 67 KB)

Sanofi Aventis (PDF 125 KB)

Welsh Assembly Government (PDF 42 KB)

Waxman (PDF 29 KB)

Prostate cancer (hormone refractory) - docetaxel (final appraisal determination) information

Prostate cancer (hormone refractory) - docetaxel (final appraisal determination) (PDF 116 KB)

Response to consultee, commentator and public comments on the ACD (PDF 82 KB)

Prostate cancer (hormone refractory) - docetaxel (appraisal consultation) information

Prostate cancer (hormone-refractory) - docetaxel: overview (PDF 123 KB)

Prostate cancer (hormone-refractory) - docetaxel - Assessment report addendum (PDF 16 KB)

Prostate cancer (hormone-refractory) - docetaxel: assessment report (PDF 1.15 MB)

Prostate cancer (hormone-refractory) - docetaxel: Consultee and commentator comment on the assessment report

British Prostate Cencer Group (PDF 67 KB)

Cancer BACUP (PDF 16 KB)

Institute of Cancer Research (PDF 59 KB)

NHS Quality Improvement Scotland (PDF 33 KB)

Prostate Cancer Charity (PDF 57 KB)

Prostate Cancer Guideline Group (PDF 14 KB)

Royal College of Nursing (PDF 17 KB)

Royal College of Pathologists (PDF 15 KB)

Royal College of Physicians (PDF 44 KB)

Sanofi-Aventis (Formerly known as Aventis Pharma Ltd) (PDF 171 KB)

Prostate cancer (hormone-refractory) - docetaxel: non manufacturer submissions

Cancer BACUP (PDF 39 KB)

Royal College of Nursing (PDF 15 KB)

Royal College of Pathologists (PDF 14 KB)

Royal College of Physicians, the Association of Cancer Physicians, the Royal College of Radiologists and the Joint Collegiate Council for Oncology (joint submission (PDF 24 KB)

Sanofi-Aventis (Formerly known as Aventis Pharma Ltd) (PDF 39 KB)

Prostate cancer (hormone-refractory) - docetaxel: Final protocol (PDF 82 KB)

Prostate cancer (hormone-refractory) - docetaxel: Final scope (PDF 27 KB)

Prostate cancer (hormone-refractory) - docetaxel: Summary of consultee and commentator comments of the draft scope (PDF 23 KB)

Prostate cancer (hormone-refractory) - docetaxel: Summary of consultee and commentator comments on the draft matrix (PDF 14 KB)

Prostate cancer (hormone-refractory) - docetaxel: draft scope (PDF 28 KB)

Prostate cancer (hormone-refractory) - docetaxel: provisional matrix of consultees and commentators (PDF 27 KB)

2004/027 NICE asked to develop guidance on the care of drug misuse, medicines for prostate cancer, and management of attention deficit hyperactivity disorder information